United States

Agenus Inc (AGEN.O)

AGEN.O on Consolidated Issue listed on NASDAQ Capital Market

2 Dec 2016
Change (% chg)

$0.15 (+3.80%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for AGEN.O


Agenus Inc. (Agenus) is an immuno-oncology company. The Company is engaged in discovering and developing treatments for patients with cancer. Its approaches are driven by platforms and programs, which include antibody discovery platform, including Retrocyte Display, SECANT yeast display and phage display technologies designed to... (more)


Beta: 2.79
Market Cap(Mil.): $426.30
Shares Outstanding(Mil.): 87.00
Dividend: --
Yield (%): --


  AGEN.O Industry Sector
P/E (TTM): -- 42.21 29.87
EPS (TTM): -1.35 -- --
ROI: -65.75 -1.09 14.95
ROE: -417.20 -2.39 16.29

BRIEF-Agenus reports Q3 loss per share $0.47

* Agenus reports third quarter financial results and recent highlights

Oct 27 2016

BRIEF-Agenus Q2 loss per share $0.33

* Agenus reports second quarter 2016 financial results and operational progress

Jul 28 2016

BRIEF-Agenus' chief financial officer, C.Evan Ballantyne to resign

* On july 14, 2016, C. Evan Ballantyne, chief financial officer informed agenus of his intention to resign - sec filing

Jul 19 2016

BRIEF-Agenus Inc starts phase 1/2 clinical trial of anti-GITR agonist antibody

* Expect to initiate additional clinical studies with antibodies and immuno-oncology leads from comprehensive pipeline in next twelve months

Jun 22 2016

BRIEF-Agenus announces lead product candidate selection in Merck collaboration

* Agenus announces lead product candidate selection in its collaboration with Merck

Jun 09 2016

Earnings vs. Estimates